Literature DB >> 6323667

Efficacy of topical antibiotic therapy in acute conjunctivitis in children.

F Gigliotti, J O Hendley, J Morgan, R Michaels, M Dickens, J Lohr.   

Abstract

We studied 102 children aged 1 month to 18 years in a randomized, double-blind trial designed to determine both the natural history of bacterial conjunctivitis and whether topical antibiotic therapy is beneficial. Affected eyes were treated four times a day for 7 days with drug (polymyxin-bacitracin ophthalmic ointment) or placebo. Eighty-four patients had proved bacterial conjunctivitis (Haemophilus influenzae 61, Streptococcus pneumoniae 22, both one); 66 of these received only topical therapy. By 3 to 5 days, 21 of 34 (62%) patients receiving topical antibiotic were clinically cured, whereas only nine of 32 (28%) patients given placebo were cured (P less than 0.02). By 8 to 10 days, 31 (91%) of the patients given antibiotic and 23 (72%) of the placebo group were cured (P = NS). The bacterial pathogen was eradicated by day 3 to 5 in 71% and by day 8 to 10 in 79% of patients given antibiotic, compared to 19% and 31% of the placebo group (P less than 0.001). Acute bacterial conjunctivitis is a self-limited disease, but topical antibiotic therapy with polymyxin-bacitracin shortens the duration of clinical disease and enhances eradication of the causative organism from the conjunctiva.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323667     DOI: 10.1016/s0022-3476(84)80566-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

Review 1.  Topical antibiotics for acute bacterial conjunctivitis: a systematic review.

Authors:  A Sheikh; B Hurwitz
Journal:  Br J Gen Pract       Date:  2001-06       Impact factor: 5.386

Review 2.  Eye disorders: bacterial conjunctivitis.

Authors:  C W Chung; E J Cohen
Journal:  West J Med       Date:  2000-09

3.  Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary.

Authors:  Adebukola Adebayo; Jignesh G Parikh; Steven A McCormick; Mahendra K Shah; Remedios S Huerto; Guopei Yu; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-08       Impact factor: 3.117

4.  Safety and efficacy of topical norfloxacin versus tobramycin in the treatment of external ocular infections.

Authors:  J A Jacobson; N B Call; E M Kasworm; M S Dirks; R B Turner
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 5.  Bacterial conjunctivitis.

Authors:  John Epling
Journal:  BMJ Clin Evid       Date:  2012-02-20

Review 6.  Treatment of ocular infections with topical antibacterials.

Authors:  J P Leeming
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 7.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  Acute infectious conjunctivitis in childhood.

Authors:  R Chawla; J D Kellner; W F Astle
Journal:  Paediatr Child Health       Date:  2001-07       Impact factor: 2.253

9.  An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite.

Authors:  David Granet; Steven J Lichtenstein; Bruce Onofrey; James A Katz
Journal:  Clin Ophthalmol       Date:  2007-12

10.  Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis.

Authors:  Susannah McLean; Aziz Sheikh
Journal:  Patient Prefer Adherence       Date:  2010-05-13       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.